Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, USA.
Cancer Invest. 2021 Apr;39(4):315-320. doi: 10.1080/07357907.2021.1903914. Epub 2021 Mar 26.
Outcomes for patients (pts) with sarcoma and COVID-19 are unknown. This is a single institution retrospective study of adults with sarcoma and COVID-19. Ten pts [median age 60 (range 24-69)] were identified. Five were hospitalized; two died from COVID-19 complications; another died from sarcoma. Time between last systemic treatment dose and COVID-19 diagnosis was 6-41 days in pts who died. 5 underwent prior radiation (RT); time between RT and COVID-19 diagnosis was 20-62 days for pts who died. All three pts with WBC differential data (two died) were lymphopenic. Efforts to capture outcomes for a larger cohort are urgently needed.
患有肉瘤和 COVID-19 的患者的预后情况尚不清楚。这是一项针对患有肉瘤和 COVID-19 的成年人的单机构回顾性研究。共确定了 10 名患者[中位年龄 60 岁（范围 24-69 岁）]。其中 5 名患者住院治疗；2 名患者因 COVID-19 并发症死亡；另一名患者因肉瘤死亡。死亡患者最后一次全身治疗剂量与 COVID-19 诊断之间的时间间隔为 6-41 天。5 名患者接受了放射治疗（RT）；死亡患者 RT 与 COVID-19 诊断之间的时间间隔为 20-62 天。所有 3 名具有白细胞分类数据的患者（2 人死亡）均为淋巴细胞减少症。迫切需要努力获取更大队列的结果数据。
